Pathos AI raises $237M Series E for AI-powered oncology drug development

Pathos AI, a biotech company using artificial intelligence to develop cancer drugs, closed a $237 million Series E funding round at a $3 billion post-money valuation. The round represents a significant jump from the company's $1.6 billion valuation just six months earlier in May 2025.

The funding milestone reflects growing investor appetite for AI applications in drug discovery and precision medicine, where machine learning can accelerate the identification and development of oncology treatments.